期刊
CANCER SCIENCE
卷 112, 期 4, 页码 1357-1368出版社
WILEY
DOI: 10.1111/cas.14799
关键词
antigen loss; chimeric antigen receptor; dual‐ target; hematological malignancies; relapse
类别
资金
- Natural Science Foundation of Guangdong Province, China [2018B030311042]
- Frontier Research Program of Bioland Laboratory (Guangzhou Regenerative Medicine and Health Guangdong Laboratory) [2018GZR110105014]
- Science and Technology Planning Project of Guangdong Province, China [2017A020215043]
- Science and Technology Program of Guangzhou, China [201704020216]
- Clinical Research Startup Program of Southern Medical University by High-level University Construction Funding of Guangzhou Provincial Department of Education [LC2016ZD027]
- President Foundation of Zhujiang Hospital, Southern Medical University [yjjj2019qn07]
CD19-specific CAR T-cell therapy has shown significant efficacy in treating B-cell hematological malignancies, but targeted antigen-negative relapse poses a challenge to its widespread application. Researchers have explored alternative targets and tested combination antigen CAR T-cell therapies to enhance treatment effectiveness.
In recent years, the excellent curative effect of CD19-specific chimeric antigen receptor (CAR) T-cell therapy has brought hope to patients with relapsing or refractory B-cell hematological malignancies, however relapse after CAR T-cell infusion has hindered the widespread clinical application of this immunotherapy and targeted antigen-negative relapse has caused widespread concern. Consequently, strategies for increasing targeted antigens have been created. In addition to the most widely applied target, namely CD19, researchers have further explored the possibility of other targets, such as CD20, CD22, CD33, and CD123, and have tested a series of combination antigen CAR T-cell therapies. Here, we summarize the current preclinical and clinical studies of dual-target CAR T cells.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据